Investor Spotlight: Texas Biomedical Research Institute

Since its founding in 1941 by Thomas B. Slick Jr., Texas Biomedical Research Institute has gained worldwide recognition in scientific and academic communities for the quality of its basic and translational research programs. Texas Biomedical Research Institute employs over 350 people, including several hundred health professionals such as veterinarians, scientists in many fields, and physicians. Texas Biomedical Research Institute’s impact is not just seen in San Antonio; their research is making a difference and making lives better across the world.

“San Antonio provides a unique, highly advantageous location from which we execute our mission of protecting you, your family and our global community from the threat of infectious diseases,” Dr. Larry Schlesinger, President/CEO says. “Its geographic location in the south central United States provides easy access for collaborators worldwide, as well as an optimal location to reach populations who provide great potential for research.” Dr. Schlesinger also cites the city’s military presence as a way to capitalize on knowledge transfer.

Infectious diseases are growing and spreading faster than ever before. Because of Texas Biomedical Research Institute, some of the world’s most aggressive infectious diseases like Ebola and Zika could be cured here in San Antonio. Texas Biomedical Research Institute’s BSL-4 contract research program was involved in the testing of several compounds to treat infection from the Ebola virus. Two of those drugs are showing great promise in saving lives in Africa. Someday, these drugs may be stockpiled to protect everyone from this deadly virus.

Additionally, the Department of Defense is trying to speed up the process of finding an effective vaccine for the emerging Zika virus, which is a particular threat to pregnant women. In 2019, as part of a program called the Congressionally Directed Medical Research Program, the Department of Defense awarded Texas Biomedical Research Institute $2 million over the next three years to study a promising experimental Zika vaccine.

“Healthcare and bioscience is San Antonio’s number one industry and the city’s research portfolio boasts more than $1 billion in funded science. Bioscience is a hypercompetitive environment and collaboration is key to securing new research dollars,” said Dr. Schlesinger.

In an unprecedented feat of cross-organizational collaboration, Texas Biomedical Research Institute is working with UT Health San Antonio, the University of Texas at San Antonio, and Southwest Research Institute to form the San Antonio Partnership for Precision Therapeutics. The partnership aims to change how healthcare providers approach treatments through individualized interventions. This is only possible in San Antonio because of a culture rooted in collaboration and a demographically diverse population that is reflective of the projected demographics in the U.S. in the future.

Texas Biomedical Research Institute’s collaborative nature and expertise in innovation make it a premier institution with a global reach. Its solutions to problems have gained worldwide recognition and through these innovations, may create scientific breakthroughs that help those suffering from life-threatening diseases.

To learn more about Texas Biomedical Research Institute, visit